PMID- 37601075
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230823
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 14
DP  - 2023
TI  - Real-world experience with selinexor-containing chemotherapy-free or low-dose 
      chemotherapy regimens for patients with relapsed/refractory acute myeloid 
      leukemia and myeloid sarcoma.
PG  - 1217701
LID - 10.3389/fphar.2023.1217701 [doi]
LID - 1217701
AB  - Introduction: Treatment of relapsed or refractory acute myeloid leukemia (R/R 
      AML) and myeloid sarcoma (MS) has presented challenges for decades. Studies on 
      selinexor in combination with various standard or intensive chemotherapy regimens 
      for the treatment of R/R AML have demonstrated promising results. This study 
      aimed to evaluate the efficacy and safety of chemotherapy-free or low-dose 
      chemotherapy regimens with selinexor for R/R AML and MS patients. Methods: Ten 
      patients with R/R AML or MS who received chemotherapy-free or low-dose 
      chemotherapy regimens in combination with selinexor at Tongji Hospital from 
      October 2021 to August 2022 were included in this study. The primary endpoint was 
      overall response rate (ORR) and secondary endpoints included complete remission 
      (CR), CR with incomplete hematological recovery (CRi), partial remission (PR), 
      transplantation rate, and safety. Results: All patients were evaluable for 
      response, achieving CR in four (40.0%) patients and CRi in two (20.0%) patients 
      for a total CR/CRi of 60.0%. The ORR was 80.0% when patients with PR were 
      included. Five (50.0%) patients underwent allogeneic hematopoietic stem cell 
      transplantation (allo-HSCT) after treatment with selinexor-containing regimens. 
      At the end of the follow-up, seven (70.0%) patients were alive, and three 
      patients died of transplant-related complications or disease progression. The 
      most frequently reported nonhematologic adverse events (AEs) in patients were 
      grade 1 or 2 asymptomatic hyponatremia. Conclusion: The chemotherapy-free or 
      low-dose chemotherapy regimens in combination with selinexor for R/R AML are 
      feasible and tolerable and provide an opportunity for patients to receive 
      transplantation.
CI  - Copyright (c) 2023 Tong, Jin, Xu, Su, Li, Li, Peng, Mao, Huang and Zhang.
FAU - Tong, Xiwen
AU  - Tong X
AD  - Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan, Hubei, China.
FAU - Jin, Jie
AU  - Jin J
AD  - Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan, Hubei, China.
FAU - Xu, Bin
AU  - Xu B
AD  - Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan, Hubei, China.
FAU - Su, Shuai
AU  - Su S
AD  - Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan, Hubei, China.
FAU - Li, Li
AU  - Li L
AD  - Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan, Hubei, China.
FAU - Li, Mengyuan
AU  - Li M
AD  - Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan, Hubei, China.
FAU - Peng, Yizhou
AU  - Peng Y
AD  - Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan, Hubei, China.
FAU - Mao, Xia
AU  - Mao X
AD  - Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan, Hubei, China.
FAU - Huang, Wei
AU  - Huang W
AD  - Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan, Hubei, China.
FAU - Zhang, Donghua
AU  - Zhang D
AD  - Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan, Hubei, China.
LA  - eng
PT  - Journal Article
DEP - 20230804
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC10436481
OTO - NOTNLM
OT  - acute myeloid leukemia
OT  - chemotherapy-free
OT  - refractory
OT  - relapsed
OT  - selinexor
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/08/21 06:42
MHDA- 2023/08/21 06:43
PMCR- 2023/08/04
CRDT- 2023/08/21 04:54
PHST- 2023/05/05 00:00 [received]
PHST- 2023/07/24 00:00 [accepted]
PHST- 2023/08/21 06:43 [medline]
PHST- 2023/08/21 06:42 [pubmed]
PHST- 2023/08/21 04:54 [entrez]
PHST- 2023/08/04 00:00 [pmc-release]
AID - 1217701 [pii]
AID - 10.3389/fphar.2023.1217701 [doi]
PST - epublish
SO  - Front Pharmacol. 2023 Aug 4;14:1217701. doi: 10.3389/fphar.2023.1217701. 
      eCollection 2023.